MedTrace Logo

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

NCT01488279 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-03-12

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.

Conditions

  • Pre-diabetes
  • Impaired Fasting Glucose
  • Impaired Glucose Tolerance

Interventions

DRUG

Dexamethasone 2.5 mg and Sitagliptin 100 mg

Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days

DRUG

Dexamethasone 2.5 mg and placebo tablet

Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days

Sponsors & Collaborators

  • University of Vermont

    lead OTHER

Principal Investigators

  • Annis M Marney, MD, MSCI · University of Vermont

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-07-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488279 on ClinicalTrials.gov